Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 6, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The Healey ALS Platform Trial learns from successful cancer drug studies to identify and accelerate new treatments for the devastating disease.
An international panel of MS and radiology experts discuss optimizing a standardized examination, how MRI should be used in a clinical setting, and the need to be internationally aligned.
Patients with relapsing multiple sclerosis showed declining scores on tests of cognitive processing speeds from baseline to 3-month follow-up post-relapse.
Philippa Cheetham, MBChB, MRCS, MD, FRCS, leads a discussion on the long-term management of spinal muscular atrophy, and the importance of genetic testing for individuals with SMA who are planning a family.
The chief executive officer of Clene Nanomedicine discussed CNM-Au8, their novel investigational drug that will be used in the world’s first platform trial of potential ALS treatments.